@article{ART002998781},
author={Sun L Riehm},
title={An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib},
journal={CELLMED},
issn={3022-6805},
year={2023},
volume={13},
number={12},
pages={1-7}
TY - JOUR
AU - Sun L Riehm
TI - An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib
JO - CELLMED
PY - 2023
VL - 13
IS - 12
PB - Cellmed Orthocellular Medicine and Pharmaceutical Association
SP - 1
EP - 7
SN - 3022-6805
AB - Objective: A case of reducing adverse effects associated with imatinib using Cyaplex F.
Methods: The 52-year-old female with past medical history of stage 1 triple-positive breast cancer 10 years ago, and current metastatic melanoma has been complaining adverse effects after imatinib was started.
Results: After OCNT was initiated, the patient’s headache and muscle pain have been much tolerable and her AST/CPK levels were returned close to her baseline.
Conclusion: OCNT may reduce side effects caused by Imatinib and help patient to stay with the current chemotherapy regimen.
KW - Ortho-Cellular Nutrition Therapy (OCNT);breast cancer;melanoma;headache;muscle pain;AST;CPK
DO -
UR -
ER -
Sun L Riehm. (2023). An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib. CELLMED, 13(12), 1-7.
Sun L Riehm. 2023, "An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib", CELLMED, vol.13, no.12 pp.1-7.
Sun L Riehm "An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib" CELLMED 13.12 pp.1-7 (2023) : 1.
Sun L Riehm. An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib. 2023; 13(12), 1-7.
Sun L Riehm. "An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib" CELLMED 13, no.12 (2023) : 1-7.
Sun L Riehm. An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib. CELLMED, 13(12), 1-7.
Sun L Riehm. An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib. CELLMED. 2023; 13(12) 1-7.
Sun L Riehm. An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib. 2023; 13(12), 1-7.
Sun L Riehm. "An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib" CELLMED 13, no.12 (2023) : 1-7.
